Analyzing cancer cells using mitochondrial DNA to understand tumor diversity
Clonal analysis of cancer by mitochondrial DNA barcoding
This study is looking at how different types of cancer cells develop and change within tumors, using special markers in their DNA to understand their unique characteristics, which could help create more personalized and effective treatments for patients.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11075869 on NIH RePORTER |
What this research studies
This research investigates the complex mixture of different cell types within tumors, focusing on how clonal evolution leads to the emergence of genetically distinct cancer cell populations. By utilizing mitochondrial DNA as natural barcodes, the researchers aim to profile these cells at a single-cell level, examining their transcriptional and epigenetic states. This approach seeks to uncover the underlying mechanisms of tumor heterogeneity and identify potential vulnerabilities in cancer cells, ultimately guiding the development of more effective therapies. Patients may benefit from insights that could lead to personalized treatment strategies targeting specific tumor cell populations.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia or related conditions who are seeking innovative treatment options.
Not a fit: Patients with solid tumors unrelated to acute myeloid leukemia may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies that effectively target and eradicate diverse cancer cell populations, improving treatment outcomes for patients.
How similar studies have performed: Previous research has shown promise in using mitochondrial DNA barcoding for cancer analysis, indicating that this approach may yield valuable insights into tumor biology.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Van Galen, Peter — Brigham and Women's Hospital
- Study coordinator: Van Galen, Peter
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.